RTP Mobile Logo

Friday, May 1, 2020, San Antonio, Texas, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA CNE (NCPD) Symposia Series Associated with the ONS 45th Annual Congress

Locally Advanced Non-Small Cell Lung Cancer

Update regarding COVID-19

The ONS Board of Directors has made the difficult decision to cancel the 45th Annual ONS Congress scheduled to take place in San Antonio, April 29-May 3, 2020. ONS is exploring alternatives for delivering the educational sessions. For up-to-date information on this program, please sign up for our email alerts.

Last updated 4/8/2020

Event Details

Location
Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)
Schedule
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
 
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Faculty
Beth Eaby-Sandy, MSN, CRNP, OCN
Nurse Practitioner
Outpatient Thoracic Oncology
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Benjamin Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Medical Director, Thoracic Oncology Program
Johns Hopkins Sidney Kimmel Cancer Center at
Sibley Memorial
Washington, DC

Stephen V Liu, MD, PhD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Elizabeth S Waxman, RN, MSN, ANP-BC
Nurse Practitioner in the Department of
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida
 
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP during the Oncology Nursing Society’s (ONS) 45th Annual Congress, April 29 to May 3, 2020 in San Antonio, Texas. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

Agenda

Topics for Discussion

  • Module 1: Current Role of Durvalumab Consolidation for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
  • Module 2: Optimal Timing of Durvalumab Following the Completion of CRT; Impact of Radiation-induced Toxicities on its Use
  • Module 3: Spectrum, Frequency and Management of Immune-Mediated Adverse Events (AEs) with Anti-PD-1/PD-L1 Antibodies; Contraindications to Their Use
A detailed agenda will be made available by late March.

CE Information

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Appreciate the benefits, risks and long-term outcomes associated with current local and/or systemic treatment modalities in the management of resectable or unresectable locally advanced non-small cell lung cancer (NSCLC), and consider this information when counseling patients.
  • Evaluate available research data documenting the efficacy and safety of sequential anti-PD-L1 antibody therapy for patients with unresectable locally advanced NSCLC.
  • Review the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Develop an understanding of which clinical and biologic factors (eg, chemoradiation therapy-related toxicities, PD-L1 status, EGFR or ALK status) are relevant in the decision to use anti-PD-L1 antibody consolidation therapy for unresectable Stage III NSCLC to better counsel patients about current therapeutic recommendations.
  • Recognize immune-related adverse events and other common side effects of anti-PD-L1 antibody consolidation therapy in patients with Stage III NSCLC, and offer supportive strategies to minimize and/or manage these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with locally advanced NSCLC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Location

Grand Hyatt San Antonio
600 East Market Street
San Antonio, TX 78205

Hotel Phone: (210) 224-1234

Meeting Room
Texas Ballroom ABC (Fourth Floor)

The Grand Hyatt San Antonio is conveniently located adjacent and connected to the Henry B Gonzalez Convention Center, where the ONS 45th Annual Congress is taking place.